Cordlife India, the leading umbilical cord and cord blood processing, testing and cryopreservation facility in the country has partnered with Dr Michael Chez, autism and epilepsy treatment pioneer from Sutter Neuroscience Institute to study the treatment of childhood autism using cord blood stem cells.

Autism is now the leading cause of childhood neuro-developmental morbidity. According to the recent data published, more children than ever before are being diagnosed with autism, with one in 160 children worldwide suffering from autism spectrum disorder.

Research suggests there is a “multi-hit theory” as to why certain children develop symptoms of autism. Most cases appear to be due to a combination of genetics and environmental factors. There are a number of research studies being undertaken worldwide to investigate the effects of cord blood stem cells that can potentially restore brain function in people with similar disorders. If successful, the therapy can potentially decrease disabilities and improve quality of life for millions.

Cord blood that remains in the umbilical cord and placenta following the birth of a newborn is a rich source of hematopoietic stem cells, which have proven useful in the treatment of over 80 diseases including certain cancers and blood disorders.

Dr Michael Chez managing director, neurologist; director of pediatric neurology at Sutter Memorial Hospital, director of the pediatric epilepsy and autism programs for the Sutter Neuroscience Group said,“My working partnership with Cordlife was based upon my research interest in childhood autism and the global need for advancing treatment in autism. Cordlife India, being the pioneer of stem cell banking in India would help me to extend my research by interacting and working with reputed physicians from the sub-continent. Together we hope to improve the quality of life of patients with autism.”

Meghnath Roy Chowdhury, managing director of Cordlife India said, “We are excited to have Dr Chez, in India with us to work with physicians here to study the treatment of childhood autism using cord blood stem cells. Consistent with our mission, this initiative demonstrates our commitment to play our part in contributing towards medical options available to families who have stored their children’s cord blood”.